FibroGen Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for anemia, fibrotic diseases, and chronic kidney disease
The organization focuses on the development of novel treatments that harness the body's natural processes to promote healthy red blood cell production and reduce fibrosis, thereby addressing significant unmet medical needs. Through its cutting-edge research and clinical trials, FibroGen aims to improve patient outcomes and enhance the quality of life for individuals suffering from these serious health conditions.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.
FibroGen reports topline results from late-stage trials of pamrevlumab for pancreatic cancer, failing to meet the primary endpoint of overall survival.
FibroGen Inc (NASDAQFGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron.
